ATLANTA, March 28, 2017 -- DLH Holdings Corp. (NASDAQ:DLHC), a leading provider of innovative health services and solutions to Federal agencies, is pleased to announce winning the U.S. Navy’s Clinical Preceptorship Program (CPP) contract. DLH Mission Services and Solutions (formerly Danya International LLC) has managed CPP since 2003, providing senior behavioral health practitioners who deliver clinical supervision, training, and mentoring to the Navy’s Alcohol and Drug Counselors. This mission-critical work has supported clinical supervision of counselors working in more than 50 Substance Abuse Rehabilitation Programs worldwide. The goal of these expert providers, called Preceptors, is to help U.S. Navy counselors in increasing their counseling capabilities by providing specialized training for continuous improvement of quality service delivery. The base contract with options has a total value to DLH of $6.5 million.
DLH is honored to continue providing support to the nation’s sailors and their family members through CPP. “We have a solid track record of producing results — a 14-year history of providing qualified professionals to support Navy counselors in achieving maximum effectiveness via on-the-job mentoring and in-depth clinical supervision,“ said DLH Mission Services and Solutions President Helene Fisher. “Our record of exemplary service is gratifying. Going forward, we will continue to provide first-rate service through our corporate commitment to excellence in support of our service members’ readiness and resiliency, in a manner consistent with the Navy’s commitment to readiness sustainability.”
DLH Executive Vice President John Armstrong, FACHE (USA, COL, RET), added, “Our overall mission is continuous program improvement through quality service and designated counselors. We will continue to meet expectations by adhering to current standards and by remaining sensitive to the health counseling needs of the Department of the Navy, our military personnel, and their families.”
About DLH
DLH (NASDAQ:DLHC) serves clients throughout the United States as a healthcare and human services provider to the Federal Government. The company’s core competencies include assessment and compliance monitoring, business process outsourcing, health information technology systems integration and management, readiness and medical logistics, and pharmacy solutions. DLH has more than 1,400 employees working throughout the country. For more information, visit the corporate website at www.dlhcorp.com.
CORPORATE COMMUNICATIONS Contact: Tiffany McCall Phone: 404–334–6000 Email: [email protected] INVESTOR RELATIONS Contact: Chris Witty Phone:646–438–9385 Email: [email protected]


NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 



